Sam Chun Dang Pharm Signs U.S. Licensing Deal for Oral Obesity Drug; $150 Million Milestone

U.S. Licensing Rights for Rybelsus and Wegovy Oral Generics

Quarterly Settlement of Net Profits... 90% Allocated to Sam Chun Dang Pharm

Sam Chun Dang Pharm announced on March 30 that it has signed a U.S. licensing agreement with its American partner for the generics of the oral diabetes medication "Rybelsus" and the oral obesity treatment "Wegovy Oral" (active ingredient: semaglutide).

The total milestone amount is $100 million (approximately 150.8 billion won).

Net profits generated from product sales will be settled and distributed on a quarterly basis. For 10 years from the first day of sale, Sam Chun Dang Pharm will receive 90% and the partner company 10%. If the partner company fails to achieve 50% of the expected sales for two consecutive years, Sam Chun Dang Pharm has the right to terminate the agreement or change the contract terms.

The company cited its "SNAC-Free" technology as the background for this agreement.

Wegovy's developer, Novo Nordisk, has registered a formulation patent related to the absorption enhancer SNAC through 2039. However, Sam Chun Dang Pharm explained that it avoided patent infringement by developing an alternative substance that maximizes absorption without SNAC, utilizing its proprietary "S-PASS" platform.

This content was produced with the assistance of AI translation services.